Value | Category | Cases | |
---|---|---|---|
1 | End of course of treatment | 0 |
0%
|
2 | Poor adherence | 1 |
0.3%
|
3 | Intolerance - Rash | 1 |
0.3%
|
4 | Intolerance - Hepatitis | 2 |
0.6%
|
5 | Lactataemia | 7 |
2.3%
|
6 | Lactic Acidosis | 16 |
5.1%
|
7 | Neuropathy | 16 |
5.1%
|
8 | Lipodystrophy | 104 |
33.4%
|
9 | Immunological failure | 0 |
0%
|
10 | Virological failure | 15 |
4.8%
|
11 | Planned interruption | 0 |
0%
|
12 | Other | 51 |
16.4%
|
13 | Unknown | 0 |
0%
|
14 | Entry Required | 18 |
5.8%
|
15 | Policy change | 62 |
19.9%
|
16 | TasP trial switch to Atripla | 18 |
5.8%
|
Sysmiss | 10692 |